“Starting with Oncology, we expect at least 12 further updates by the end of 2024.”

In context

“re in the US to 48%. Oncology grew 37% to almost $3 billion, an increase of almost $800 million in just one year. This growth was split evenly between our Kite cell therapies and Trodelvy. Veklury for COVID-19 contributed $2.2 billion in 2023, ahead of our expectations, but down year-over-year, as expected, given the evolution of the pandemic. In the last two years combined, Gilead’s base business has grown approximately $3.3 billion, or more than 7% annually, largely offsetting the decline in Veklury revenues over the same period. The consistent growth in our base business gives us a strong foundation as we continue into 2024 and look to deliver on our broad clinical portfolio. This is a catalyst-rich phase for Gilead with more than 20 updates this year and many more to come beyond 2024. Starting with Oncology, we expect at least 12 further updates by the end of 2024. These include Phase 3 updates for Trodelvy in bladder and triple-negative breast cancer, and results from the pivotal Phase 2 iMMagine-1 study for anito-cel in multiple myeloma, for which we saw encouraging Phase 1 data at the American Society of Hematology meeting in December. Also in Cell Therapy, we are very pleased to have shortened our manufacturing time for Yescarta by another two days in the US, reinforcing our industry-leading median turnaround time, which is now at an anticipated 14 days. As you know, we did not reach the primary endpoint for EVOKE-01, our Phase 3 trial for second-line plus metastatic non-small cell lung cancer. Merdad will go into detail on this later, but while we did not see the outcome we hoped for, the data are encouraging on a number of levels, namely, a nu”